This profile was last updated on //
Is this you? Claim your profile.
WuXi PharmaTech Inc.
288 Fute Zhong Road Waigaoqiao Free Trade Zone
WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing
Find other employees at this company (29)
(166 Total References)
WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
July 10, 2008 - Shanghai, China - WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.
Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda.
Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences.
In addition, Dr. Yu
has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration
(FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company
She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.
responsibilities in her
new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives.
Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
"With 19 years of experiences in venture capital and life sciences, Debra
will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."
Dr. Yu received her BA in Molecular Biology from Princeton University, New Jersey in 1986 and her MD from Harvard Medical School, Massachusetts in 1992.
Debra Yu, Managing Director, ...
Debra Yu, Managing Director, Labrador Advisors
Debra Yu, MD co-authors "Institutionalizing Externalization at Big Pharma - The Third Leg" with Andrew Baum, which appears in the March 2012 issue of IN VIVO magazine
Debra Yu, MD contributes to Andrew Baum's report entitled "Shrink, Smarten, Spin: Three 'Killer Apps' for Unlocking Pharma R&D Value" published by Citi Research
Debra Yu, MD co-authors "WuXi's Customer Focused Business Model Shows the Changing Relationship Between Drug Makers and CROs" with Richard Soll, which appears in the June 2009 issue of IN VIVO magazine
Debra Yu, MD is profiled in "The Dean's Report: Harvard Medical School 2007-2008," pages 45-46
May 19, 2008
Debra Yu, MD speaks in New York, NY on a panel entitled "Pfizer Venture Investments: A Vehicle for Change" at the New York Biotechnology Association 17th Annual Meeting
April 1, 2007
Debra Yu, MD is quoted in the "Pharma Venturing in Diagnostics" section of "Wake-up Calls in IVD" by Mark Ratner and Tom Salemi, which appears in the April 2007 issue of IN VIVO magazine
Debra Yu, MD moderates panel discussion at Windhover's START-UP Forum in May 2003, which is detailed in "Beyond Vanilla VC: Tough Times Demand Clever Measures" by Deborah Erickson, which appears in the May 2003 issue of START-UP magazine
Labrador is led by Debra Yu, MD, who is a hands-on operator with a distinctive and unique skill set having worked in venture capital, business development, strategy, banking and management consulting.
She has held positions both in private firms as well as inside companies - both in Big Pharma and small and emerging-growth environments.
Debra brings perspectives from all sides of the table, and works actively to bridge parties to drive deals to closure.
Debra Yu, MD, Managing Director of Labrador Advisors, has over 20 years of experience in the life sciences industry and possesses a unique skill set having worked in venture capital, business development, strategy, banking and management consulting.
In addition to heading Labrador, she also serves on the editorial board of Elsevier's Pharmasia News and is the Midatlantic Regional Chairperson for Bayhelix, a China-US cross-border, life sciences industry organization.
Previously, she was VP of Strategy at WuxiApptec (NYSE: WX), one of the world's leading outsourced services company, based in Shanghai, China.
Debra began her industry training at Morgan Stanley and then worked at McKinsey & Co., in New York and London.
She then served as a general partner of two prominent bay area venture capital firms, Delphi Ventures and Bay City Capital.
time in California, in her
capacity as a Director of the Permanente Company
helped Kaiser Permanente
, a leading Health delivery organization, build an in-house venture capital group.
After returning to the East Coast in the early 2000s, she
built and co-led Pfizer's
venture capital group in New York.
While at Pfizer
led activities related to asset monetization/asset divestiture and led the groundbreaking work which resulted in the initiation of Pfizer's
was also involved in Pfizer's
Diagnostics Council and was an active participant in Pfizer's
Debra has stewarded more than 25 companies through venture capital, sat on the board of 8 and stepped in as CEO of one.
has held internships at the U.S. FDA, The Wilkerson Group and Genentech
Debra received a BA with high honors in Molecular Biology from Princeton in 1986 and earned an MD from Harvard Medical School in 1992.
Debra is a Governor of the Asian American Alumni Association of Princeton and serves as the group's Treasurer and a member of the Biology Council, Institute for Advanced Studies in Princeton, NJ.